Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals

Lynk Pharmaceuticals and Formation Bio Enter Exclusive Development and Licensing Agreement for LNK01006

HANGZHOU, China and SHANGHAI and BOSTON, Dec. 10, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals') and Formation Bio...

Formation Bio Licenses Phase 1-Ready CNS Penetrant TYK2 Inhibitor from Lynk Pharmaceuticals

/PRNewswire/ -- Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a...

Formation Bio gains global rights to Lynk Pharma's TYK2 inhibitor

Formation Bio has acquired the global rights, excluding in Greater China, to LNK01006 from Lynk Pharmaceuticals.

Exclusive: AI unicorn Formation Bio licenses a TYK2 drug from China

Since Takeda paid billions for Nimbus Therapeutics' program in 2022, TYK2 has been one of immunology's hottest targets. But it's also crowded, with biotechs herding into the signs of success and interest ...